TY - JOUR
T1 - Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia
T2 - a National Cancer Database analysis of 2221 patients
AU - Dhakal, Prajwal
AU - Lyden, Elizabeth
AU - Joshi, Utsav
AU - Pyakuryal, Avantika
AU - Loh, Kah Poh
AU - Klepin, Heidi
AU - Bhatt, Vijaya Raj
N1 - Funding Information:
Kah Poh Loh reports serving as a consultant for Pfizer and Seattle Genetics and receiving honoraria from Pfizer. Heidi Klepin has contributed to UpToDate. Vijaya Raj Bhatt reports participating in Safety Monitoring Committee for Protagonist, and receiving consulting fees from Genentech, Incyte, Servier Pharmaceuticals LLC, and Abbvie, research funding (institutional) from Abbvie, Pfizer, Incyte, Jazz, and National Marrow Donor Program, and drug support (institutional) from Oncoceutics for a trial. There are no conflicts of interest for any other authors.
Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Association between comorbidity burden and patient outcomes has not been adequately investigated in acute promyelocytic leukemia (APL). We utilized the National Cancer Database to evaluate the association of the Charlson–Deyo Comorbidity Index (CCI) with one-month mortality and overall survival (OS) in adults ≥60 years with APL. One-month mortality was 16%, 24%, and 32%, and 3-year OS was 61%, 53%, and 38% for patients with CCI 0, 1, and ≥2, respectively. One-month mortality was higher for patients with CCI 1 (OR 1.67, 95% CI 1.29–2.16, p <.001) and CCI ≥ 2 (OR 2.31, 95% CI 1.70–3.13, p <.001) compared to patients with CCI 0. Patients with CCI 1 (HR 1.27, 95% CI 1.10–1.46, p <.001) and CCI ≥ 2 (HR 1.74, 95% CI 1.48–2.06, p <.001) had worse OS compared to patients with CCI 0. In conclusion, CCI is an independent predictor of survival outcomes in patients with APL.
AB - Association between comorbidity burden and patient outcomes has not been adequately investigated in acute promyelocytic leukemia (APL). We utilized the National Cancer Database to evaluate the association of the Charlson–Deyo Comorbidity Index (CCI) with one-month mortality and overall survival (OS) in adults ≥60 years with APL. One-month mortality was 16%, 24%, and 32%, and 3-year OS was 61%, 53%, and 38% for patients with CCI 0, 1, and ≥2, respectively. One-month mortality was higher for patients with CCI 1 (OR 1.67, 95% CI 1.29–2.16, p <.001) and CCI ≥ 2 (OR 2.31, 95% CI 1.70–3.13, p <.001) compared to patients with CCI 0. Patients with CCI 1 (HR 1.27, 95% CI 1.10–1.46, p <.001) and CCI ≥ 2 (HR 1.74, 95% CI 1.48–2.06, p <.001) had worse OS compared to patients with CCI 0. In conclusion, CCI is an independent predictor of survival outcomes in patients with APL.
KW - Acute promyelocytic leukemia
KW - National Cancer Database
KW - comorbidity
KW - older adults
KW - one-month mortality
KW - overall survival
UR - http://www.scopus.com/inward/record.url?scp=85146252783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146252783&partnerID=8YFLogxK
U2 - 10.1080/10428194.2023.2165394
DO - 10.1080/10428194.2023.2165394
M3 - Article
C2 - 36629003
AN - SCOPUS:85146252783
SN - 1042-8194
VL - 64
SP - 691
EP - 697
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -